A recent study [27] reported the overexpression of CLDN4 in platinum-resistant EOC patients compared to platinum-sensitive ones and demonstrated an increased sensitivity of ovarian cancer cells to cisplatin after in vitro suppression of CLDN4 expression by siRNA. Here, CLDN4 is linked to ovarian carcinoma.